Nigeria Customs Tariff for HS Code 293333
Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, alfentanil (INN), anileridine (INN), bezitramide (INN), bromazepam (INN), carfentanil (INN), difenoxin (INN), diphenoxylate (INN), dipipanone (INN)
Reported average: 5%.
Source year: 2023. Classification: HS 2022 (H6). Checked 2026-09-14.
National lines included: 1 of 1. Excluded from the average: 0.
Reported ad-valorem range: 5%–5%.
Reported historical ad-valorem MFN simple average for 2023, not a national tariff schedule. No preferential rates, additional duties, VAT, excise or import permissions are determined.
Not a current 2026 national duty. The HS6 average does not determine the duty of a particular national subdivision, origin or shipment.
WITS observation for this code and year
UN Comtrade H6 descriptions (HS 2022)
WITS API definitions: reported averages and excluded national lines
Direct HS code answer for Nigeria
Nigeria HS Code 293333: 5.00% (2023 MFN average)
The source reports an indicative HS6 MFN average of 5.00% (2023 MFN average) for Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, alfentanil (INN), anileridine (INN), bezitramide (INN), bromazepam (INN), carfentanil (INN), difenoxin (INN), diphenoxylate (INN), dipipanone (INN).Source status: not assessed. Verify the exact national tariff line, origin treatment, taxes, restrictions, and current customs guidance before using this information in a declaration.
Customs tariff summary
- Country
- Nigeria
- HS / tariff code
- 293333
- Description
- Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, alfentanil (INN), anileridine (INN), bezitramide (INN), bromazepam (INN), carfentanil (INN), difenoxin (INN), diphenoxylate (INN), dipipanone (INN)
- Chapter
- 29 —
- Heading
- 2933
- Subheading
- 293333
- Indicative MFN HS6 average
- 5.00% (2023 MFN average)
- VAT / tax
- Check local VAT and excise rules for the import destination.
- Unit / basis
- Not listed in this tariff line
- Source / vintage
- WITS / UNCTAD TRAINS — 2023 MFN HS6 reference
Historical MFN average
5.00% (2023 MFN average)
Import permission
not assessed
Import planning
Need a landed cost report for this HS code?
Request a one-page research summary with source checks, landed-cost inputs, and points to verify for HS code 293333 in Nigeria.
Details
- HS Code
- 293333
- Chapter
- 29 —
- Heading
- 2933
- Subheading
- 293333
Compare HS code 293333 across GCC countries
Each destination shows its own source label. Oman uses its national schedule; Qatar and UAE entries may cite their separately published references and unresolved exceptions. Other entries retain the historical GCC reference. National codes, duty notes, restrictions and tax treatment can differ; verify with the destination customs authority.
Related HS Codes (Heading 2933)
| HS Code | Description | Duty |
|---|---|---|
| 293311 | Heterocyclic compounds; with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, phenazone (antipyrin) and its derivatives | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293319 | Heterocyclic compounds; with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293321 | Heterocyclic compounds; with nitrogen hetero-atom(s) only, containing an unfused imidazole ring (whether or not hydrogenated) in the structure, hydantoin and its derivatives | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293329 | Heterocyclic compounds; with nitrogen hetero-atom(s) only, containing an unfused imidazole ring (whether or not hydrogenated) in the structure, other than hydantoin and its derivatives | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293331 | Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, pyridine and its salts | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293332 | Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, piperidine and its salts | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293334 | Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other fentanyls and their derivatives | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293335 | Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, 3-quinuclidinol | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293336 | Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, 4-anilino-N-phenethylpiperidine (ANPP) | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293337 | Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, N-phenethyl-4-piperdone (NPP) | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293339 | Heterocyclic compounds; containing an unfused pyridine ring (whether or not hydrogenated) in the structure, n.e.c. in 2933.3 | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293341 | Heterocyclic compounds; containing a quinoline or isoquinoline ring-system (whether or not hydrogenated) in the structure, not further fused, levorphanol (INN) and its salts | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293349 | Heterocyclic compounds; containing a quinoline or isoquinoline ring-system (whether or not hydrogenated) in the structure, not further fused, other than levorphanol (INN) and its salts | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293352 | Heterocyclic compounds; containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, malonylurea (barbituric acid) and its salts | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293353 | Allobarbital (INN), amobarbital (INN), barbital (INN), butalbital (INN), butobarbital, cyclobarbital (INN), methylphenobarbital (INN), pentobarbital (INN), phenobarbital (INN), secbutabarbital (INN), secobarbital (INN) and vinylbital (INN); salts thereof | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293354 | Heterocyclic compounds; containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, other derivatives of malonylurea (barbituric acid) and salts thereof, n.e.c. in 2933.53 | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293355 | Heterocyclic compounds; containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure; loprazolam (INN), mecloqualone (INN), methaqualone (INN), and zipeprol (INN); salts thereof | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293359 | Heterocyclic compounds; containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea and its derivatives, loprazolam, mecloqualone, methaqualone, zipeprol, and salts thereof) n.e.c. in 2933.5 | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293361 | Heterocyclic compounds; containing an unfused triazine ring (whether or not hydrogenated) in the structure, melamine | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
| 293369 | Heterocyclic compounds; containing an unfused triazine ring (whether or not hydrogenated) in the structure, others excluding melamine | 5.00% (2023 MFN average)WITS 2023 historical MFN average |
Data source: WITS/UNCTAD TRAINS (MFN 2022). Values are indicative HS6 MFN averages, not shipment-specific applied rates. Import permission and restrictions are not assessed. Historical reference rates exclude VAT, excise and other national measures. Separate national entries preserve the columns printed by their source; these are not a complete shipment assessment. Full disclaimer.